

Maine Naloxone Distribution Initiative

Project-To-Date Totals through March 31, 2026

Prepared by the Margaret Chase Smith Policy Center
University of Maine

In July 2019, the Maine Naloxone Distribution Initiative (MNDI) launched an overdose education, prevention, and naloxone distribution project. Public health and harm reduction partners, known as Tier 1 Distributors, began distributing state-supplied naloxone rescue kits across Maine to clinicians, community partners, and end users. This brief provides information on naloxone distribution and reported overdose reversals by the Tier 1 organizations comprising the MNDI from the initiation of the project through March 2026, with a particular emphasis on the first quarter of 2026. Additionally, subcategories of naloxone distribution from Tier 1 organizations to the Overdose Prevention Through Intensive Outreach Naloxone and Safety (OPTIONS) initiative and syringe services/access programs in 2021 as well as EMS Naloxone Leave Behind Program are provided.

Tier 1 organizations include Bangor Public Health (BPH), Portland Public Health (PPH), MaineGeneral Health (MG), and Maine Access Points (MAP). BPH serves the Aroostook, Downeast, and Penquis public health districts, PPH serves Cumberland and York, and MG serves Central, Midcoast, and Western. MAP distributes naloxone statewide with a particular focus on rural regions. Data from the Office of the Attorney General's (OAG) law enforcement administered naloxone program have also been included to provide an overview of the combined public health, harm reduction, and public safety efforts in Maine.

Currently, it is hard to measure the effectiveness of naloxone distribution because the total number of overdose reversals relies on voluntary reporting. The distribution and reported reversal data tables and figure in this report offer conservative estimates of the lives saved through public health, harm reduction, and safety efforts, which prevented the number of drug deaths from potentially being much higher.

Monthly proportions of fatalities in January – March 2026 averaged 4.8%. During 2025, monthly proportions of fatalities averaged 5.1%, ranging from a high of 6.5% in December to a low of 3.3% in September (Sorg et al. 2026). Additional resources, data, and visualizations are available at the Maine Drug Data Hub: <https://mainedrugdata.org/>.




Figure 1: County-level naloxone distribution levels per 100 residents (with point of initial township distribution indicated by star) by the Maine Naloxone Distribution Initiative from January through March 2026.

Public Health—Tier 1 Distributors

During the first quarter of 2026 (January–March):

- 29,782** doses of naloxone have been distributed
- 297** overdose reversals have been voluntarily reported.

From July 2019 through March 2026 (MNDI project-to-date totals):

- 799,150** doses of naloxone have been distributed
- 10,553** overdose reversals have been voluntarily reported.

Public Safety—Law Enforcement Agencies

During the first quarter of 2026 (January–March):

- 1050** doses of naloxone have been distributed
- 14** overdose reversals have been voluntarily reported.

From July 2019 through December 2025:

- 24,286** doses of naloxone have been distributed
- 1,930** overdose reversals have been voluntarily reported.

Table 1 Doses of naloxone distributed by Tier 1 distributors and OAG

	2019–2024	2025	Jan 2026	Feb 2026	Mar 2026	Total
BPH (IN)	140320	41806	308	700	380	183514
BPH (RI)	4416	4152	0	4032	0	12600
BPH (IM)	0	14800	0	0	0	14800
PPH (IN)	120345	29786	1516	1246	2108	155001
PPH (IM)	3648	2130	0	0	200	5978
PPH (RI)	0	4	0	0	0	4
MG	111242	42680	1852	6744	2322	164840
MAP (IM)	163135	19470	1676	908	1612	186801
MAP (IN)	50436	4264	1322	958	1448	58428
MAP (RI)	2454	14280	104	134	212	17184
OAG	21504	1732	424	506	120	24286
Total	617500	175104	7202	15228	8402	823436

Notes: (1) Unit is doses for all values. (2) IM = intramuscular; IN = intranasal; RI = RiVive. All values are IN unless otherwise indicated. (3) MAP distribution initially included state-supplied and nonstate-supplied naloxone. (4) 2019 data is for July through December only. (5) A revision has been made to BPH 2020 and 2021 and PPH 2021, 2022 and MG 2020, 2021 and 2022. OBH 2019, 2020, 2021, and 2022. (6) Table 1 includes corrections for MAP reporting that include a decrease in IN doses and an increase in IM doses. 1957 doses of IN naloxone were removed from distribution data from 07/2019 to 07/2023 and 13926 doses of IM naloxone were added to distribution data from 07/2019 to 07/2023. (7) Beginning June of 2024, the MNDI will be purchasing and distributing lower dose (3mg) naloxone (RiVive). (8) BPH naloxone purchase and distribution was delayed Jul-Sep 2025 due to pending contracting delays. (9) The Office of the Attorney General purchase and distribution of naloxone was delayed Nov-Jan 2025 due to pending decision for continuance with the MNDI.

Table 1.1 Doses of naloxone distributed by Tier 1 distributors to OPTIONS liaisons (subcategory of total distribution)

	2021–2024	2025	Jan 2026	Feb 2026	Mar 2026	Total
BPH	12338	8132	0	0	0	20470
PPH	6698	5206	600	120	96	12720
MG	14012	4200	48	576	192	19028
Total	33048	17538	648	696	288	52218

Notes: (1) Unit is doses for all values.

Table 1.2 Doses of naloxone distributed by Tier 1 distributors through syringe services/access programs (subcategory of total distribution)

	2021–2024	2025	Jan 2026	Feb 2026	Mar 2026	Total
BPH	29798	25806	0	4032	0	59636
PPH	35047	10244	482	460	650	46883
MG	10956	1546	120	48	234	12904
MAP	130490	36558	3102	2000	3192	175342
Total	206291	74154	3704	6540	4076	294765

Notes: (1) Unit is doses for all values. (2) A revision has been made to BPH March, June, September of 2021 January, April and May of 2022 as well as PPH April 2021 and February of 2023. (3) Missing data for January 2021 for PPH.

Table 1.3 Doses of naloxone distributed by Tier 1 distributors to EMS Naloxone Leave Behind Program (subcategory of total distribution)

	2022–2024	2025	Jan 2026	Feb 2026	Mar 2026	Total
BPH	2512	646	76	276	104	3614
PPH	1738	508	64	12	74	2396
MG	3330	1736	240	600	264	6170
Total	7580	2890	380	888	442	12180

Notes: (1) Unit is doses for all values. (2) The EMS Leave Behind Program was launched in January of 2022. T1s are to provide EMS agencies across the state with kits of naloxone to provide to anyone who has refused EMS transport.

Table 2 Number of overdose reversals voluntarily reported to Tier 1 distributors (by individuals or Tier 2 distributors) and overdose reversals reported by OAG law enforcement agencies through the reporting tool called ODMAP

	2019–2024	2025	Jan 2026	Feb 2026	Mar 2026	Total
BPH	2933	421	55	58	59	3526
PPH	1746	187	13	11	15	1972
MG	1052	162	16	16	17	1263
MAP	3425	229	19	11	6	3690
OAG	1833	83	6	2	6	1930
OD-ME app	91	10	1	0	0	102
Total	11080	1092	110	98	103	12483

Notes: (1) Reversal totals are conservative estimates as not all reversals are reported. (2) OD-ME app is a mobile phone app developed in 2020 to support naloxone administration. (3) Overdose reversal figures may increase as backdated Tier 2 distributor and OAG incident reports are received. (4) 2019 data is July through December only. (5) Law enforcement agencies that receive naloxone from the OAG and report reversals through ODMAP are now being included. ODMAP reversal data has been added from July 2019 to present. (6) A revision has been made to MAP 2022 and PPH February 2023 reversal reports as well as OAG Q1 2023 and MG Q4 2025.

Works Cited

Marcella H. Sorg, Prianka Maria Sarkar, and Daniel Soucier. (2026). *Maine Monthly Overdose Report*. Orono: University of Maine, Margaret Chase Smith Policy Center.